Introduction
The company macro-level orientation is to enter into the field of modern medicine such as biotechnology, new drug delivery technologies based on nanotechnology, sustained release medicines and the development of cellular and molecular biology industries including cell therapy, gene therapy, immunotherapy and tissue engineering. The subsidiaries of Barkat Pharmaceuticals holding company are operating in the fields of developing and transferring technical knowledge , commercialization of new technologies and drug manufacturing (ranging from active pharmaceutical ingredients to finished products, business services, export, import and distribution Our company has acquired 14 percent of the country total pharmaceutical market and could produce more than 420 different products through its subsidiaries. The major shares of the subsidiaries including Alborz Investment Company and most of its subsidiaries such as Sobhan Darou Pharmaceuticals Co., Iran Daru Co., Tolid Daru Co., Alborz Darou Co. and etc, have been listed and offered in The Tehran Stock Exchange and are public companies. Through constructive interaction with knowledge-based institutions and scientists around the world, taking advantage of the knowledge and technologies in the field of health and medicine, and by cooperating with hundreds of experts and researchers, Barkat Pharmed Co. intends to contribute to the country pharmaceutical area and plays a vital role in the treatment of patients especially those who suffering from refractory diseases.
